Completion of planned enrollment in phase II MS trial
Posted: Mon Sep 19, 2011 7:01 am
Completion of planned enrollment in phase II MS trial of Trimesta™
Adeona Pharmaceuticals, Inc. announced today that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta™ (oral estriol) drug candidate for relapsing-remitting multiple sclerosis (MS) in women, per the original protocol.
The Company also announced that Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology, and lead Principal Investigator of this Phase II clinical trial, has funding available to continue enrollment at all 15 centers, therefore, increasing the power of the trial. It is anticipated that the remaining grant funding will allow for the enrollment of an additional 10-20 patients.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1878
Adeona Pharmaceuticals, Inc. announced today that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta™ (oral estriol) drug candidate for relapsing-remitting multiple sclerosis (MS) in women, per the original protocol.
The Company also announced that Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology, and lead Principal Investigator of this Phase II clinical trial, has funding available to continue enrollment at all 15 centers, therefore, increasing the power of the trial. It is anticipated that the remaining grant funding will allow for the enrollment of an additional 10-20 patients.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1878